Spravato Benefits, Cost, and Side Effects for Treatment-Resistant Depression

You’ve tried two antidepressants. Then three. Maybe four. Each time, the same pattern – initial hope, weeks of waiting, and disappointing results. Your doctor suggests another medication change, but you’re exhausted from the cycle. You wonder if anything will ever work.

I’ve seen this frustration in patients who arrive at Washington Behavioral Medicine Associates after years of ineffective treatment. Treatment-resistant depression doesn’t mean you’re failing – it means your depression requires a different approach. That’s where ketamine therapy, specifically Spravato (esketamine), changes the treatment path entirely. It works through a different mechanism than anything you’ve tried, and yes, it does come with real Spravato side effects your care team watches closely from your first session. Cost is usually the bigger worry, though – and it’s often more manageable than patients assume once insurance gets involved.

Here’s what makes ketamine therapy at WBMA different, who benefits most from Spravato treatment, and what the benefits, cost, and side effects actually look like once you start.

What Makes Spravato Different From Traditional Antidepressants

Traditional antidepressants – SSRIs like fluoxetine or sertraline, SNRIs like venlafaxine – work by increasing serotonin or norepinephrine levels in the brain. These medications take 4-8 weeks to show effects, and they don’t work for everyone. About one-third of adults with major depressive disorder don’t respond adequately to at least two different oral antidepressants. That’s treatment-resistant depression, affecting an estimated 7 million adults in the United States.

Spravato (esketamine) operates through an entirely different mechanism. It’s a non-competitive antagonist of the NMDA receptor, which means it blocks certain glutamate receptors in the brain. Glutamate is the most abundant excitatory neurotransmitter in your nervous system, playing roles in learning, memory, and neural plasticity.

The exact mechanism by which esketamine produces antidepressant effects remains under investigation, but research suggests it may promote rapid synaptogenesis – the formation of new neural connections. Traditional antidepressants slowly adjust neurotransmitter levels; Spravato appears to help the brain build new pathways around the circuits affected by depression.

This difference in mechanism translates to differences in results. While SSRIs require weeks of daily pills before you notice improvement, Spravato has shown promise in reducing depressive symptoms within 24 hours for some patients. In the clinical trial supporting the January 2025 FDA approval of Spravato as monotherapy, patients experienced improvements as early as 24 hours that were sustained through 28 days of treatment.

Who Benefits From Spravato Treatment

Spravato isn’t a first-line depression treatment. The FDA approves it specifically for adults with major depressive disorder who have had inadequate response to at least two oral antidepressants. This is treatment-resistant depression.

You might be a candidate for Spravato if:

• You’ve tried multiple antidepressants without adequate symptom relief
• You can’t tolerate the side effects of oral antidepressants
• You need faster symptom improvement than traditional medications provide
• Your depression symptoms significantly impair daily functioning despite current treatment

Spravato is also FDA-approved in conjunction with an oral antidepressant for treating depressive symptoms in adults with major depressive disorder who have acute suicidal ideation or behavior. This application addresses the critical need for rapid symptom relief in psychiatric emergencies.

At WBMA, we conduct a thorough psychiatric evaluation before recommending Spravato. This includes reviewing your complete medication history, assessing your current depression severity, evaluating your cardiovascular health, and discussing your treatment goals and ability to commit to the required monitoring protocol.

The Benefits of Spravato for Treatment-Resistant Depression

Rapid Symptom Improvement

The most significant benefit of Spravato is speed. Depression steals weeks, months, sometimes years from people’s lives. Traditional antidepressants require 4-8 weeks before you know if they’re working. Spravato may begin reducing symptoms within hours to days.

In the phase 4 trial that supported the 2025 monotherapy approval, patients taking Spravato alone showed a statistically significant improvement in Montgomery-Asberg Depression Rating Scale scores by week four – with 22.5% achieving remission, compared to 7.6% on placebo, according to the manufacturer’s FDA approval announcement. While individual responses vary, many patients report noticing changes faster than with oral medications.

This rapid onset matters enormously when depression is interfering with your ability to work, maintain relationships, or function daily. The weeks you would spend waiting for an SSRI to work are weeks you get back.

Different Mechanism When Others Haven’t Worked

If you’ve tried multiple SSRIs or SNRIs without success, your depression likely doesn’t respond well to serotonin-based interventions. Continuing to try different medications in the same class rarely produces better results. Spravato offers a genuinely different approach through the glutamate system.

Real-world data reported by the manufacturer indicate that a large number of patients worldwide have received Spravato treatment since its initial approval, with continued use across multiple countries. This extensive real-world evidence supports what clinical trials demonstrated – for many people with treatment-resistant depression, glutamate-targeting therapy can be an effective option when serotonin-targeting medications aren’t.

Flexibility in Treatment Approach

The FDA’s January 2025 approval expanded how Spravato can be used. Previously, patients had to take Spravato in conjunction with an oral antidepressant. Now, Spravato can be prescribed as monotherapy for treatment-resistant depression.

This flexibility may benefit patients who experience intolerable side effects from oral antidepressants or have medical conditions that make certain oral antidepressants risky. It also simplifies treatment for patients who achieve symptom control with Spravato alone, reducing the need for daily medication management.

Sustained Response with Maintenance Treatment

Spravato treatment follows an induction phase where you receive more frequent doses, followed by a maintenance phase with less frequent administration. Research indicates that patients who respond to Spravato during induction and continue maintenance treatment often experience sustained symptom improvement and reduced time to relapse compared to discontinuing treatment.

This means Spravato doesn’t just provide short-term relief – it can be part of a long-term management strategy for treatment-resistant depression.

What to Expect During Spravato Treatment at WBMA

Spravato treatment differs significantly from taking a daily pill. Because of potential side effects and safety considerations, esketamine is available only through the Spravato Risk Evaluation and Mitigation Strategy (REMS) program in certified healthcare settings.

Treatment Administration

Spravato comes as a nasal spray. Each device delivers 28 mg of esketamine. Depending on your prescribed dose (56 mg or 84 mg), you’ll use two or three devices with a five-minute rest between each device.

You self-administer the nasal spray under medical supervision at our clinic. A healthcare provider guides you through proper administration technique and monitors you throughout the process.

Monitoring Requirements

After each dose, you’ll remain at the clinic under observation for at least two hours. This monitoring is required because Spravato can cause sedation, dissociation, and temporary blood pressure increases.

During the monitoring period, we check your blood pressure at 40 minutes and 90 minutes post-dose. We also assess for adverse effects, including dissociation, dizziness, nausea, or increased anxiety.

Most patients tolerate Spravato well, and these effects typically resolve during the two-hour monitoring period. You cannot drive yourself home after treatment – you’ll need to arrange transportation.

Treatment Schedule

Spravato treatment follows a structured protocol:

• Induction phase (weeks 1-4): You’ll receive treatment twice weekly. This intensive initial phase establishes therapeutic response.
• Maintenance phase (week 5 onward): Treatment frequency decreases to once weekly, then may decrease further to once every two weeks depending on your response and symptoms.

The exact schedule is individualized based on how you respond, side effect tolerance, and depression severity. Some patients achieve remission with less frequent dosing; others need more consistent treatment for optimal symptom control.

Managing Spravato Side Effects

Concerns about Spravato side effects are one of the biggest reasons patients hesitate before trying it. Here’s what treatment actually involves, and how we manage it.

What Dissociation Actually Feels Like

Dissociation is the Spravato side effect most patients ask about before their first session. Many describe a temporary sense of detachment from their body, thoughts, or surroundings, sometimes with mild visual or perceptual changes. This typically begins within minutes of dosing and resolves within the two-hour monitoring period.

Our clinical team stays with you throughout this window, checking your blood pressure and monitoring how you’re doing rather than leaving you alone with an unfamiliar sensation. Many patients find the experience unusual rather than distressing once they know what to expect going in.

Common Side Effects and How We Manage Them

Most Spravato side effects are manageable and short-lived. Here’s what shows up most often:

• Sedation affects a substantial share of patients in clinical trials (48-61%), typically most noticeable in the first hour after dosing
• Dizziness and nausea are usually mild and tend to resolve during the observation period
• Temporary blood pressure elevation is monitored at 40 and 90 minutes post-dose, with dose adjustments available if needed

As treatment continues, many patients find these effects decrease in intensity. We manage them through dose adjustments when needed, adequate monitoring, and a calm, comfortable treatment environment.

Long-Term Safety Considerations

Spravato Cost & Insurance Coverage

Cost is often the first question patients ask, and it’s a fair one. Spravato without insurance can run into the thousands of dollars for a full induction course, but most WBMA patients don’t pay anything close to that.

• Insurance coverage: because Spravato is FDA-approved for treatment-resistant depression, most major commercial plans cover it under the medical benefit once prior authorization criteria are met.
• The part patients are usually most relieved to hear: many commercially insured patients qualify for the manufacturer’s savings program, which can bring the cost of each session down to as little as $10 for eligible patients.
• Prior authorization is the administrative step – your care team documents that you’ve tried at least two oral antidepressants without adequate relief before your insurer approves coverage.
• If you’re on Medicare or Medicaid, the manufacturer’s copay program won’t apply, though Medicare Part B often covers a portion of treatment cost. Patient responsibility still varies by plan.

We verify your insurance benefits before treatment begins and walk you through what to expect for your specific plan, including any concurrent oral antidepressant costs if you’re prescribed one alongside Spravato. That number is different for every patient, honestly – coverage and out-of-pocket costs vary by plan and individual circumstances, so our team gives you a specific estimate once we’ve verified your benefits rather than a one-size-fits-all figure.

Ketamine Therapy Research for Other Mental Health Conditions

While Spravato is FDA-approved specifically for treatment-resistant depression and acute suicidal ideation in major depressive disorder, research continues on ketamine therapy for other psychiatric conditions. It’s important to distinguish between FDA-approved uses and research applications.

PTSD Research

Studies have investigated intravenous ketamine for post-traumatic stress disorder, particularly when combined with trauma-focused psychotherapy. Some research has reported improvements in PTSD symptoms, depression, anxiety, and sleep quality among patients receiving ketamine therapy.

The proposed mechanism involves ketamine creating a controlled dissociative state that may help patients process trauma without reexperiencing fear. Some studies have combined ketamine with prolonged exposure therapy or other trauma interventions.

Anxiety Disorder Research

Limited research has explored ketamine for anxiety disorders, including generalized anxiety disorder and social anxiety disorder. Some studies report rapid reduction in anxiety symptoms, but research remains preliminary.

Ketamine’s dissociative effects create theoretical concerns about worsening anxiety in some patients, so this application requires careful study. Currently, no ketamine formulation is FDA-approved for anxiety disorders.

At WBMA, we focus on evidence-based, FDA-approved applications of treatment. While we stay informed about emerging research, we recommend Spravato specifically for its approved indication: treatment-resistant depression in adults who have not responded to at least two oral antidepressants.

How Spravato Fits Into Your Complete Treatment Plan

Ketamine therapy through Spravato isn’t a standalone solution – it works best as part of an integrated treatment approach. At WBMA, we combine Spravato with other evidence-based interventions matched to your specific needs.

Your treatment plan might include Spravato for rapid symptom reduction, individual therapy to address thought patterns and coping skills, medication management if you’re taking oral antidepressants alongside Spravato, and lifestyle support including sleep, exercise, and stress management. Spravato is one part of WBMA’s broader neuromodulation services, which also include TMS, neurofeedback, and other interventional options when a different approach fits better.

For some patients, Spravato provides the symptom relief needed to engage more effectively in therapy. Depression’s cognitive effects – difficulty concentrating, negative thinking, low energy – can make therapy less productive. When Spravato reduces these symptoms, therapy often becomes more effective.

We also coordinate with your other healthcare providers. If you’re working with a primary care physician, therapist outside our practice, or specialists for other health conditions, we maintain communication to track your full treatment picture.

Frequently Asked Questions

If you’re weighing Spravato against other ketamine-based options, our guide to ketamine therapy in Washington DC covers IV ketamine and other delivery methods available at WBMA.

Individual results may vary. Treatment effectiveness depends on each patient’s unique circumstances – schedule a consultation to discuss whether Spravato may be right for you.